The North Sea Race Endurance Exercise Study
Launched by HELSE STAVANGER HF · Jun 15, 2014
Trial Information
Current as of July 21, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The North Sea Race Endurance Exercise Study is looking at how intense exercise, like a long cycling race, affects heart health in healthy athletes. Specifically, the study focuses on measuring levels of a protein called cardiac troponin I (cTnI), which can indicate heart damage after strenuous exercise. Researchers want to understand if higher levels of this protein are linked to heart disease and other heart-related issues in people who participate in a 91-kilometer cycling competition.
To join the study, participants should be healthy individuals who are signed up for the North Sea Race and have completed an online questionnaire before the event. Unfortunately, those with heart disease, high blood pressure, diabetes, or those on heart medications cannot participate. While the trial is currently active, they are not recruiting new participants at this time. This study will help clarify the impact of high-intensity exercise on heart health and may provide important insights for athletes and health professionals alike.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • participants in the "North sea race"
- • presumably healthy persons
- • signed informed consent
- • answered internet based questionnaire prior to the race
- Exclusion Criteria:
- • cardiac disease
- • hypertension
- • diabetes mellitus
- • use of primary cardiovascular medical prevention
About Helse Stavanger Hf
Helse Stavanger HF is a leading healthcare organization based in Norway, dedicated to providing high-quality medical services and advancing clinical research. As a prominent sponsor of clinical trials, Helse Stavanger HF focuses on innovative therapeutic interventions across various medical fields, aiming to enhance patient care and outcomes. With a commitment to ethical research practices and collaboration with academic institutions, the organization plays a vital role in the development of new treatments and the improvement of healthcare standards in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stavanger, , Norway
Patients applied
Trial Officials
Stein Ørn, MD PhD
Principal Investigator
Helse Stavanger HF
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials